Lymphoma Clinical Trials

Showing 1181-1200 of 3,379 trials

Glofitamab in Chinese Patients With R/R DLBCL

NCT06481826

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

DLBCL - Diffuse Large B Cell Lymphoma

Peking Union Medical College Hospital20 participantsStarted Jan 2024

Beijing, Beijing Municipality, China

TERMINATEDPhase 1

Phase I/II Study of Avelumab in Pediatric Cancer Participants

NCT03451825

This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumors (including central nervous system tumors) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy. The study was planned to be conducted in 2 parts: the dose-finding part (Phase I) and the tumor-specified expansion part (Phase II). However, Phase II was cancelled due to limited clinical benefit of PD-L1 monotherapy in pediatric participants.

Refractory or Relapsed Solid TumorsLymphoma

EMD Serono Research & Development Institute, Inc.21 participantsStarted Mar 2018

Aurora, Colorado, United States • The Bronx, New York, United States • Brussels, Belgium +8 more locations

Glofitamab in Chinese Patients With R/R DLBCL

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Related Searches

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

Imaging Apoptosis for Lymphoma Treatment Response

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

VircapSeq Virus Detection in Sézary Syndrome

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy